M.D., CMO Dr. Nussbaum has served as Invitae’s Chief Medical Officer since August 2015. Prior to joining Invitae, he was chief of the Division of Genomic Medicine at UCSF Health where he also held leadership roles in the Cancer Genetics and Prevention Program beginning in January 2009 and the Program in Cardiovascular Genetics beginning in July 2007. From April 2006 to August 2015, he served as a member of the UCSF Institute for Human Genetics. Prior to joining UCSF Health, Dr. Nussbaum was chief of the Genetic Disease Research Branch of the National Human Genome Research Institute, one of the National Institutes of Health, from 1994 to 2006. He is a member of the Institute of Medicine and a fellow at the American Academy of Arts and Sciences. Dr. Nussbaum is a board-certified internist and medical geneticist who holds a B.S. in Applied Mathematics from Harvard College and an M.D. from Harvard Medical School in the Harvard-MIT joint program in Health Sciences and Technology. He completed his residency in internal medicine at Barnes-Jewish Hospital and a fellowship in medical genetics at the Baylor College of Medicine.
M.D.Dr. Pineda is a board-certified clinical molecular geneticist and clinical cytogeneticist. Prior to joining Invitae, Dr. Pineda was the Senior Laboratory Director at Courtagen Life Sciences and Associate Clinical Director of Cytogenomics at GeneDx. There, he led the implementation of numerous clinical laboratory test, genomic variant interpretation, and reporting processes. He was instrumental in the development and launch of several genetic diagnostic tests in cytogenetics, oncology, cardiology, mitochondrial, metabolic, endocrine, neurologic, and pediatric disorders. Dr. Pineda obtained his M.D. from Universidad CES in Medellin, Colombia, and later pursued post-doctoral training at the Medical Genetics Branch of the National Human Genome Institute (NHGRI), NIH. Subsequently, he completed his American Board of Medical Genetics and Genomics (ABMGG)-accredited fellowship in clinical molecular genetics and clinical cytogenetics at the NIH Medical Genetics and Genomic Medicine Fellowship Training Program. Daniel participates in several workgroups in the Clinical Genome Resource (ClinGen), seeking improved access, quality, and consistency of genetic diagnostic tests.
Ph.D., FACMGDr. Aradhya is a board-certified molecular geneticist and cytogeneticist who has helped shape professional practices and technology applications in clinical genetic testing over the past 15 years. He joined Invitae to help bring genetics into mainstream medicine by innovating laboratory technologies, fostering advances in evidence-based clinical standards, and building mechanisms to empower individuals globally to access their genetic information. Before Invitae, Swaroop was VP and senior laboratory director for Neurogenetics and Clinical Microarrays at GeneDx. He completed medical genetics training in 2007 at Stanford University and received his Ph.D. in molecular and human genetics in 2001 at Baylor College of Medicine. Over the course of his career, he has participated in the international Human Genome Project to sequence the X chromosome and helped characterize several genetic disorders. He is currently a ClinGen investigator, serves on the Board of Directors of the American Board of Medical Genetics and Genomics, and is an adjunct clinical associate professor at Stanford University School of Medicine.
Ph.D., FACMG Dr. Buckley is board-certified in clinical molecular genetics by the American Board of Medical Genetics and Genomics. Prior to joining Invitae, Dr. Buckley was an assistant laboratory director at Counsyl specializing in carrier screening; before that, she was a molecular geneticist at PreventionGenetics with a focus on epilepsy. Dr. Buckley received her doctorate in genetics from the University of Wisconsin-Madison and completed her clinical molecular genetics training at Johns Hopkins.
M.D., Ph.D., FACMG Dr. Esplin is board-certified in clinical genetics and internal medicine. Prior to joining Invitae, he practiced clinical genetics at Kaiser Permanente's San Francisco Medical Center. Dr. Esplin completed the medical scientist training program at the University of Texas Southwestern and obtained a doctorate in genetics, with an emphasis in cancer genetics, along with his medical degree. After his internal medicine residency at UT Southwestern, he was appointed assistant professor of the University of Texas Southwestern Department of Internal Medicine. He also practiced as a hospitalist at the Dallas VA Medical Center. Dr. Esplin completed his clinical fellowship training in medical genetics at Stanford University. He pursued his postdoctoral fellowship in genetics and genomics under Mike Snyder in Stanford's department of genetics, during which time he was supported by an award from the Tashia and John Morgridge Endowed Postdoctoral Fellowship program and by the National Institutes of Health-funded Stanford Clinical and Translational Science Award.
Ph.D., FACMGDr. Hambuch joined Invitae in 2016 to focus on clinical genetic testing applications in pediatrics. She is a diplomate of the American Board of Medical Genetics, a fellow of the American College of Medical Genetics, and a member of the American Society of Human Genetics, Association for Molecular Pathologists, and American Society of Human Genetics. Prior to joining Invitae, Dr. Hambuch was instrumental in launching the first CLIA-certified, and CAP-accredited laboratory offering genome sequencing at Illumina where, over eight years, she built and oversaw a team that implemented and improved the analytical and clinical components of clinical testing and reporting for genome scale testing. She also launched a certified training program for laboratory technicians. Dr. Hambuch earned her Ph.D. at UC Berkeley, was a post-doctoral fellow at the CDC, an assistant professor at University of Munich, and was a scientist at Ambry Genetics. Her medical molecular genetics training was performed at UCLA. She serves on multiple working groups and has authored multiple publications on the standards, guidelines, and applications of clinical next-generation sequencing.
Ph.D., FACMGDr. Haverfield is board-certified in clinical molecular genetics and has more than 12 years of experience in the medical genetics field. Prior to joining Invitae, Dr. Haverfield was the director of the whole exome sequencing program at GeneDx; before that, she was the assistant director of the genetic services laboratory at the University of Chicago. Dr. Haverfield earned her Master of Science in human biology and her doctorate in biological anthropology from the University of Oxford in Oxford, England. While she was earning her doctorate and through her post-doctoral fellowship at Oxford, Dr. Haverfield worked with professors Ryk Ward and Sir David Weatherall on genetic modifiers of sickle-cell disease. She then spent two years as a post-doctoral fellow in clinical pharmacology and pharmacogenomics, studying genetic variation in drug-metabolizing enzyme genes, before completing her board-accredited clinical molecular genetics training at the University of Chicago.
Ph.D., FACMG Dr. Hovanes received her B.S. degree in genetics from the University of California, Davis, and her Ph.D. in molecular biology from the University of California, Irvine. She completed her clinical cytogenetics and clinical molecular genetics trainings at the Cedars-Sinai Medical Center and University of California Los Angeles Intercampus Medical Genetics Training Program. She is a diplomat of the American Board of Medical Genetics as a Clinical Cytogeneticist and Clinical Molecular Geneticist. Her research projects in molecular biology have focused on characterization of structure and function of a number of genes implicated in human diseases. Prior to joining Invitae and CombiMatrix, Dr. Hovanes held positions as Assistant Director at the Molecular Laboratory at Esoterix and at the Genetics Department at US LABS.
Ph.D., FACMGDr. Johnson is board-certified in clinical molecular genetics and clinical biochemical genetics by the American Board of Medical Genetics and Genomics. She is also board-certified in Clinical Chemistry by the American Board of Bioanalysis. Prior to joining Invitae, Dr. Johnson was the assistant lab director of the Clinical Biochemical Genetics Diagnostic Laboratory at the University of Miami, where she was instrumental in establishing their high-throughput enzyme testing for lysosomal storage disorders in dried blood spots. She also played an active role in the molecular diagnoses of patients with lysosomal storage disorders in the university's Clinical Molecular Genetics Diagnostic Laboratory. Dr. Johnson received her doctorate in genetics at the University of Wisconsin–Madison in 2008. She completed her clinical molecular genetics fellowship in 2011 at the University of California, San Francisco and her clinical biochemical genetics fellowship in 2012 at the University of Miami. Dr. Johnson has a special interest in lysosomal storage disorders, newborn screening and the molecular diagnosis of inborn errors of metabolism.
Kristin McDonald Gibson, Ph.D.Dr. McDonald Gibson is board-certified in clinical molecular genetics by the American Board of Medical Genetics and Genomics. Prior to joining Invitae, Dr. McDonald Gibson completed her clinical molecular genetics fellowship at The Children’s Hospital of Philadelphia where she was part of the team that developed and launched the clinical exome sequencing test for the hospital. Dr. McDonald Gibson received her doctorate in genetics and genomics from Duke University in 2013. While at Duke, she established an analysis pipeline that used exome sequencing to identify mutations that cause limb-girdle muscular dystrophy, and she was a member of a neonatal genomics exome sequencing group that investigates the causes of unexplained medical conditions in children.
Ph.D., FACMG Dr. McLaughlin is a board-certified Clinical Molecular Geneticist by the American Board of Medical Genetics and Genomics and a fellow of the American College of Medical Genetics. Prior to joining Invitae, Dr. McLaughlin was an Associate Director of Clinical Genomics and Cardiogenetics at GeneDx, where she was instrumental in developing their clinical exome sequencing program. She also previously served as an Assistant Laboratory Director at Partners HealthCare Personalized Medicine Laboratory for Molecular Medicine. Dr. McLaughlin obtained a B.S. in Diagnostic Molecular Science from Michigan State University and a Ph.D. in Human Genetics from the University of Michigan. She completed her Clinical Molecular Genetics fellowship at Harvard Medical School. She has clinical expertise in cardiogenetics, connective tissue disorders, neurogenetics, and pediatrics.
Ph.D., FACMG Dr. Robinson is board certified in clinical molecular genetics by the American Board of Medical Genetics and Genomics. She received her doctorate in genetics from Harvard University and completed her clinical molecular genetics training at the University of Utah and ARUP Laboratories. Prior to joining Invitae, Dr. Robinson was a laboratory director at Good Start Genetics, where she worked closely with the laboratory and clinical teams to ensure the quality of their carrier screening and preimplantation genetic testing results.
M.D., FACMG Dr. Trilochan Sahoo is board certified in clinical cytogenetics and genomics and has been a laboratory director at Invitae since November 2017. He was serving as the VP of Medical Affairs and laboratory director at CombiMatrix until the company’s acquisition by Invitae in late 2017. Dr. Sahoo completed his medical training in India before moving to the US for postdoctoral training at Duke University, following which he moved to Baylor College of Medicine for doing his ABMG fellowship. He stayed on as a faculty and clinical laboratory director in the Human and Molecular Genetics department at Baylor until July 2008. He subsequently served in senior positions at Signature Genomics (Spokane, WA) and Quest Diagnostics Nichols Institute (San Juan Capistrano), CA) before joining CombiMatrix in April 2014. His work included the early design, validation, and implementation of chromosomal microarrays as a diagnostic tool in clinical genetics, and he has been closely associated with the discovery of a number of recurrent microdeletion-microduplication syndromes.
Ph.D., FACMGDr. Vatta is a clinical molecular geneticist with more than 20 years of experience in cardiovascular genetic research and 10 years in cardiovascular genetic diagnostics. Before joining Invitae, Dr. Vatta was the Director of the Cardiovascular Genetics Section at the Indiana University Molecular Genetics Diagnostic Laboratory in the Division of Diagnostic Genomics and Associate Professor of Clinical Medical and Molecular Genetics at Indiana University. There, he led the development and launch of next-generation sequencing analysis for clinical testing. Dr. Vatta received his Ph.D. in molecular genetics from the Scuola Internazionale Superiore di Studi Avanzati/International School of Advanced Studies (SISSA/ISAS) in Trieste, Italy, with a thesis on the “Molecular Genetic Approach to the Study of Dilated Cardiomyopathy." Subsequently, Dr. Vatta did his post-doctoral fellowship at the Department of Pediatrics (Cardiology) at Baylor College of Medicine, Houston, TX with particular focus on cardiomyopathies and channelopathies. Later, Dr. Vatta completed the Clinical Molecular Genetics fellowship at the Department of Huma and Molecular Genetics at Baylor College of Medicine, accredited for the American Board of Medical Genetics and Genomics certification.
Ph.D., FACMG Dr. Walters-Sen is board certified in clinical cytogenetics and clinical molecular genetics by the American Board of Medical Genetics and Genomics. Prior to joining Invitae, Dr. Walters-Sen was an assistant lab director of the Laboratory for Genetics and Genomics at Cincinnati Children’s Hospital and Medical Center, where she was instrumental in implementing an algorithmic testing process for children with neurodevelopmental disorders. She also spent time at Good Start Genetics, where she was a key member of the team that brought EmbryVu, now Invitae’s PGT, to market. Dr. Walters-Sen completed her clinical cytogenetics and clinical molecular genetics fellowships at Nationwide Children’s Hospital in 2013. She received her doctorate in human genetics from Vanderbilt University in 2011. Dr. Walters-Sen has a special interest in prenatal and early postnatal genetic diagnostics.
Ph.D., FACMGDr. Wilson is a board-certified molecular geneticist in both Canada and the United States. He received his undergraduate degree in medical laboratory science and his Ph.D. in the field of cancer genetics from the University of British Columbia, which he followed with a molecular genetics fellowship at the Children's and Women's Hospital of British Columbia and the British Columbia Cancer Agency. Prior to joining Invitae, Dr. Wilson was the Associate Laboratory Director at Fulgent Diagnostics, where he was involved in many aspects of establishing the molecular diagnostic laboratory. In addition, he was a scientific editor at N-of-One, Inc., a precision-medicine company in the oncology market.
Ph.D., FACMGDr. Winder has been involved with genetic diagnosis of neuromuscular disorders for 15 years. Prior to joining Invitae, he was co-director at PreventionGenetics, where he oversaw neuromuscular testing. His efforts there led to the availability of affordable tests for inherited muscle and nerve disorders, many of which had previously been unavailable in North America. Dr. Winder completed his medical genetics training in 2002 at the University of Iowa and is certified by the American Board of Medical Genetics and Genomics in clinical molecular genetics. He was an assistant professor in the department of pathology at the University of Iowa; he was also co-director of the university's molecular pathology laboratory until 2007.
Ph.D., FACMG Dr. Zhu is board certified in clinical molecular genetics and has more than 18 years of experience in molecular genetics and over six years of experience in clinical molecular genetics. Prior to joining Invitae, Dr. Zhu was laboratory director at Good Start Genetics, where she performed clinical duties on next-generation sequencing-based preimplantation and carrier screening for inherited disorders. Dr. Zhu received her medical training from Tianjin Medical University in China and practiced as an ENT physician there prior to coming to the US. She then earned a Master of Science in human pathology and a doctorate in cell and molecular biology from Michigan State University, where she studied the molecular mechanisms of hearing loss and lysosomal storage diseases. She then spent two years doing her postdoctoral fellowship in the department of genetics at Harvard Medical School with a focus on the identification of genes causing congenital heart disorders using next-generation sequencing. There, she gained extensive experience in designing and developing next-generation sequencing-based disease panels. Afterward, Dr. Zhu completed her clinical molecular genetics training at Boston University.
M.S.Sienna is a licensed, board-certified genetic counselor, specializing in Proactive genetic testing. Prior to joining Invitae in 2015, she was a laboratory genetic counselor at GeneDx, where she worked with the cardiovascular genetic team. Sienna is an active member of the National Society of Genetic Counselors (NSGC) and NSGC’s Precision Medicine special interest group. She holds a Master of Science in genetic counseling from Wayne State University.
M.S., CGCSherry R. Boyar is a board-certified genetic counselor who joined Invitae as a Clinical Science Liaison in 2017. Prior to joining Invitae, she was a senior genetic counselor in the Division of Medical Genetics at the Icahn School of Medicine’s Department of Genetics and Genomic Sciences, where she specialized in hereditary predisposition to cancer. Before this, she was a senior genetic counselor at Memorial Sloan-Kettering Cancer Center for approximately 9 years. During her career, Sherry has counseled thousands of patients who sought information about their hereditary cancer risk and the available options to both clarify and reduce this risk. She has also provided clinical supervision and didactic training to genetic counseling graduate students and other medical professionals seeking clinical experience and guidance in cancer genetic counseling and testing. Sherry received her undergraduate degree from Brandeis University and an M.S. in genetic counseling in 2005 from the Mount Sinai School of Medicine in New York City.
M.S., LCGCSamantha is a board-certified genetic counselor. Prior to joining Invitae she worked at the Dana-Farber Cancer Institute in Boston, where she saw adult patients with personal and family histories of cancer. She worked to expand the Dana-Farber program to several satellite locations and established an affiliate telemedicine program with Concord Hospital in New Hampshire. She also participated in several clinical research projects, including one that provided genetic counseling and multi-gene panel testing to men with prostate cancer. Samantha has a special interest in Li-Fraumeni syndrome and is part of the Li-Fraumeni Syndrome Association’s (LFSA) Genetic Counseling Advisory Board. She is a member of the National Society of Genetic Counselors (NSGC) as well as the Cancer and Cardiovascular Special Interest Groups. Samantha received her Masters of Science in Genetic Counseling from Boston University and holds a Bachelor of Science in Biology from Gettysburg College.
M.S.Amy is a licensed, board-certified genetic counselor. Prior to joining Invitae, she was a pediatric genetic counselor at Children’s Hospitals of Minnesota. Amy previously worked at GeneDx and Johns Hopkins University School of Medicine specializing in inherited heart disease. Amy is a member of both the National Society of Genetic Counselors (NSGC) and the society’s cardiovascular genetics special interest group. She holds a Master of Science in genetic counseling from Northwestern University and a Bachelor of Arts, majoring in biological and chemical sciences, from Wells College.
M.S.Tali is a licensed and board-certified genetic counselor with more than thirteen years of combined clinical counseling and laboratory experience and expertise in adult and cancer genetics. Tali has worked at Cedars-Sinai Medical Center, the Roy and Patricia Disney Family Cancer Center and the USC Norris Comprehensive Cancer Center. She has also worked in cancer genetics research on testicular cancer and carcinoma in situ of the breast. Through the organization GeneTestNow, she has been involved in promoting genetic carrier screening. Tali joined Invitae after having been an Invitae customer; she currently leads our Clinical Consultation Services. She is an active member of the National Society of Genetic Counselors (NSGC), Southern California Genetic Counselors (SCGC) and the American Society of Human Genetics. Tali holds a Bachelor of Science from Pennsylvania State University, where she majored in genetics and developmental biology, a Master of Science in genetic counseling from California State University, Northridge and a Master of Business Administration from American Jewish University.
M.S.Leslie is a board-certified genetic counselor with nearly 20 years of experience in various specialties in clinical genetics. She has provided clinical care and healthcare education in both academic and industry-based settings, including Wake Forest University School of Medicine, Mission Hospital, University of North Carolina at Greensboro, Genome Medical, and Thermo Fisher Scientific. Leslie is an active member of the National Society of Genetic Counselors (NSGC) serving as chair of the Jane Engelberg Memorial Fellowship and co-chair for the Audrey Heimler Special Projects Award. She obtained her undergraduate degree from DePauw University and went on to pursue a Master of Science from The University of Texas Genetic Counseling Program. She also obtained a certificate from the City of Hope’s Intensive Course in Genomic Cancer Risk Assessment in 2007.
Mary E. Freivogel
M.S., GGCMary is a Past President of the National Society of Genetic Counselors. As a cancer genetic counselor, her recent career path has been focused primarily on breast cancer risk assessment and cancer genetic counseling within the setting of a high-volume breast imaging center. Starting in February 2019, she began a role with Invitae, where she leads marketing efforts directed towards clinicians in the United States. Mary is actively involved with breast cancer risk assessment efforts in conjunction with various organizations, including the National Accreditation Program for Breast Centers and the National Consortium of Breast Centers, as well as the American Cancer Society and HCA/Sarah Cannon. She has presented information at various professional meetings, as well as published on this topic in national, peer-reviewed journals. Mary is passionate about the genetic counseling profession and takes a special interest in the areas of efficiency and alternative models of service delivery. She believes wholeheartedly that genetic counselors have an infinite number of talents and unique contributions to provide to clinical care, research, teaching, industry, and countless other areas. Mary is a Colorado native and lives in a suburb of Denver with her husband, Mike, and sons J.D. and Nolan. She is passionate about watching her kids play sports and when she has time for herself, she loves to run. You can often find her at a local park asking strangers if she can pet their dogs. If she could have any superpower, it would be to be able to survive without sleep, as there are usually not enough hours in the day for her to accomplish everything she wants to do.
M.S.Amy is board-certified by the American Board of Genetic Counseling. Before joining Invitae, Amy was a laboratory genetic counselor at GeneDx and a pediatric genetic counselor at Children’s National Medical Center in Washington, D.C. At GeneDx, Amy specialized in molecular cytogenetic testing and diagnostic exome sequencing. She is an active member of the National Society of Genetic Counselors (NSGC). Amy holds a Bachelor of Science in biology from James Madison University and a Master of Science in genetic counseling from University of South Carolina.
M.S.Jenna is a board-certified and licensed genetic counselor with experience in genetic variant classification and microarray interpretation and reporting. She began her career in 2013 as a clinical laboratory-based cancer reporting genetic counselor at Ambry genetics and has since gained experience in exome and microarray interpretation and reporting. Jenna is passionate about teaching and has led workshops on variant classification to the genetic counseling community. Jenna graduated from Penn State University in 2008 with a Bachelor of Science in biological anthropology and she obtained her Master of Science in genetic counseling from California State University, Stanislaus in 2013.
M.S., LCGCDaniela Iacoboni is a licensed, board-certified genetic counselor with over 19 years of clinical and diagnostic laboratory experience. She provided prenatal/preconception genetic counseling in New York City before taking a pediatric/laboratory position at Michigan State University. At MSU, Daniela was clinical supervisor and performed SNP whole genome microarray interpretation. She also held an adjunct faculty position in the College of Osteopathic Medicine. She joined Invitae in 2015 as a member of the clinical genomics cancer team, providing variant interpretation and clinical support. Daniela is a member of the National Society of Genetic Counselors (NSGC). She obtained her Bachelor of Science degree from Central Michigan University and holds a Master of Science in Human Genetics from Sarah Lawrence College.
M.S., LCGCEmily is an ABGC board-certified genetic counselor. She joined Invitae’s Clinical Consult team in 2016, bringing nine years of clinical genetic counseling experience. Immediately before joining Invitae, she worked for the Allegheny Health Network in Pittsburgh in the Cancer and Cardiovascular Genetics Programs. She provided counseling in Pittsburgh as well as multiple outreach clinics across Western Pennsylvania. Prior to that, she worked as a research coordinator and genetic counselor in the Cancer Genetics Program at the University of Pittsburgh Medical Center and as a pediatric genetic counselor at Children’s Hospital of Pittsburgh. She is an adjunct faculty member at the University of Pittsburgh and a part-time faculty member at Robert Morris University. She holds a Master of Science in genetic counseling from the University of Pittsburgh and a Bachelor of Science in biology from Penn State Behrend.
M.S., LCGCAdity is a licensed and board-certified genetic counselor with over fifteen years of experience, both in clinical counseling and as a clinical science liaison (CSL). The bulk of her experience is in prenatal and sporadic experience in both oncology as well as infertility. Adity has worked with various prominent MFM’s in the Southern California area during her time at Genzyme Genetics (now Integrated Genetics). She transitioned into industry over 5 years ago, first working as a CSL with Sequenom, with a primary focus of discussing non-invasive prenatal screening with various clinicians. Adity also has experience with tele-genetic counseling at both Genzyme and Sequenom. She is an active member of the National Society of Genetic Counselors and the Southern California Genetic Counselors association. She obtained a Bachelor of Science degree in Biology with a minor in Psychology, from the University of Southern California. She went on to pursue a Master of Science degree in Genetic Counseling from the California State University, Northridge.
M.S., LCGCKate is a licensed, board-certified genetic counselor with more than 20 years of experience. Specializing in cancer and cardiology genetics, she has provided clinical care in both academic and industry-based settings, including University Hospitals of Cleveland, Myriad, the Cleveland Clinic and GeneDx. With a passion for alternative delivery models for genetic counseling, Kate has developed telephone-based programs as a means to provide care to patients without local genetic counseling resources. Kate is a member of the National Society of Genetic Counselors (NSGC), including the cancer and cardiovascular special interest groups. She also serves as an advisory board member for the Case Western Reserve University Genetic Counseling Program. She obtained her undergraduate degree with a dual major in Biology and Psychology from Baldwin Wallace University, and went on to pursue a Master of Science in Medical Genetics from the University of Cincinnati.
M.S. Ariadna is a board-certified genetic counselor with more than 15 years of experience providing services to diverse patient populations. She has a particular interest in making genetic information, testing and counseling accessible to all those who need them. Prior to joining Invitae, Ariadna worked as a prenatal genetic counselor at UCLA-Olive View Medical Center, providing counseling services to English- and Spanish-speaking patients. She later served as a genetic counselor and research coordinator at UCLA Neuropsychiatric Institute working with parents of deaf/hard of hearing children as well as deaf/hard of hearing adults. Ariadna spent several years as a clinical genetic counselor at UCLA Jules Stein Eye Institute at the Retinal Disorders and Ophthalmic Genetics division. Ariadna subsequently joined the cardiogenetics program at Cedars-Sinai Medical Center working with individuals and families with aortopathies, cardiomyopathies, familial hypercholesterolemia, and inherited arrhythmias. At Invitae, Ariadna provides genetic counseling to individuals who undergo genetic testing for cardiovascular and cancer related genes; she is also part of the clinical consult services team. Ariadna is a member of the National Society of Genetic Counselors and has a Masters in Human Genetics from the University of California in Los Angeles and a Masters in Genetic Counseling from California State University, Northridge.
M.S.Sara is board certified by the American Board of Genetic Counseling and licensed in the state of California. Prior to joining Invitae, she was a clinical genetic counselor at Sutter Health. In this position, Sara primarily helped build the Oncology Genetics Clinic. She also provided preconception and prenatal counseling, in addition to, establishing a pilot program for the General and Pediatric Genetics Clinic. She has volunteered for Bright Pink since 2015 and is very supportive of their initiative to educate young women about breast and ovarian cancer risk. She holds a Bachelor of Science in Molecular Biology from University of California, San Diego, and a Master of Science in Genetic Counseling from California State University, Stanislaus. Sara is a member of the National Society of Genetic Counselors.
M.S., CGCSharon is a board-certified genetic counselor, licensed in the state of Massachusetts, with over 18 years combined experience in both clinical and industry roles. She joined Invitae in May of 2019 as a Clinical Science Liaison in Women’s Health. Her clinical specialty is in prenatal genetics where she provided extensive genetic counseling to diverse patient populations throughout the greater New York and Boston areas. These include the Regional Medical Genetics Center at Westchester Medical Center, Lenox Hill Hospital and, the Maternal Fetal Medicine Unit at Newton Wellesley Hospital (affiliate of The Brigham and Women’s Hospital). She has also provided clinical supervision and didactic training to genetic counseling graduate students and other medical professionals seeking clinical experience and guidance in reproductive genetic counseling and testing. Prior to joining Invitae, Sharon was Director of Clinical Services at Veritas Genetics where she established and led their genetic counseling service, developed their telecounseling model for delivery of service for elective genomes, and utilized her clinical expertise for test and business development. She holds a Bachelor of Arts in Psychology from Brandeis University, and a Master of Science in Human Genetics from Sarah Lawrence College. Sharon is a member of the National Society of Genetic Counselors.
Sarah Jane Noblin
M.S., CGSSarah Jane Noblin is a board-certified genetic counselor with 20 years of clinical experience in prenatal genetics. Prior to joining Invitae in 2019, Sarah was an Associate Professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at The University of Texas McGovern Medical School at Houston. While at UT, she provided prenatal genetic counseling services to patients at LBJ Hospital, one of the Harris Health county hospitals in Houston, TX. Sarah also participated in teaching & co-coordinating didactic courses, supervising genetic counseling students in clinic, chairing research projects and was a member of the Advisory Board of the UT Genetic Counseling Program (GCP). After transitioning from her role as Associate Program Director of the UT GCP in 2015, Sarah took on the new roles of Coordinator of Recruitment & Outreach for the UT GCP and Coordinator of Genetics Education for the UT OB/GYN Residency and MFM Fellowship Programs. Sarah remains active in the UT GCP by serving on its Research and Education Fund Committee. Sarah is also active in the National Society of Genetic Counselors, currently serving on the Abstract Workgroup for the annual AEC, in addition to co-chairing the NSGCares Taskforce and served on the Board of Directors in 2017-2019. She is also a past-President of the Accreditation Council for Genetic Counseling (ACGC). Sarah earned a BS in Psychology from Texas A&M University and an MS in Genetic Counseling from The University of Texas Genetic Counseling Program. Sarah believes that everyone can benefit from genetic counseling and is interested in exploring alternative service delivery models to bring genetic counselors closer to those that will benefit from their services.
M.S., LCGCErin is a licensed, board-certified genetic counselor who specializes in reproductive genetics. Prior to joining Invitae, Erin was a counselor with the OhioHealth Maternal Fetal Medicine in Columbus, Ohio. In this role, Erin provided clinical counseling to couples experiencing high-risk pregnancies. In addition, Erin has worked as a private practice genetic counselor, counseling individuals with reproductive health concerns and direct-to-consumer genetic test results, and served on the medical advisory board of a genetic testing startup. Erin holds a Master of Science in Medical and Molecular Genetics from the Indiana University School of Medicine Genetic Counseling Training Program and a Bachelor of Science in microbiology from The Ohio State University.
M.S., LCGCRJ is a licensed, board-certified genetic counselor who specializes in reproductive genetics. Prior to joining Invitae, RJ was a counselor with the University of California San Francisco’s Center for Reproductive Health, providing clinical counseling to patients undergoing fertility treatment and considering genetic testing for themselves and embryos. Prior to that he served as the primary genetic counselor at a perinatal diagnostic center in the Central Valley of California. Apart from clinical reproductive genetics, RJ is interested in the development and implementation of genetics educational tools that aid in medical decision-making. RJ holds a Master of Science degree in human genetics and genetic counseling from Stanford University and a Bachelor of Science degree in microbiology, immunology, and molecular genetics from the University of California, Los Angeles.
M.S., LCGCJeannine is a licensed, board-certified genetic counselor specializing in reproductive genetics within the cytogenetics laboratory located in Irvine. Prior to joining Invitae, she worked in a variety of industry-based settings including Ambry Genetics and Fulgent, specializing in test utilization management, variant interpretation, and report writing. She obtained her Bachelor of Science in Biological Sciences from Illinois State University and her Master of Science in Genetic Counseling from the University of California, Irvine.
M.S., CGCJill is a board certified genetic counselor with 14 years of experience. Prior to joining Invitae as a Clinical Science Liaison in 2017, she was a cancer genetic counselor at the Cleveland Clinic for over a dozen years. She has always had a passion for expanding access to genetic counseling services and created access to clinical care at several regional hospitals within the Cleveland Clinic and also was a consultant for PWN Health, providing telegentics and consumer initiated testing oversight. Jill obtained her Bachelor of Arts in psychology from Ohio Wesleyan University, and went on to pursue a Master of Science degree in genetic counseling from the University of North Carolina at Greensboro.
M.S.Jennifer is a licensed, board-certified genetic counselor who specializes in reproductive genetics. Prior to joining Invitae, Jennifer was a perinatal genetic counselor with Lucile Packard Children’s Hospital Stanford, providing clinical counseling for a wide variety of indications including family history of birth defects, intellectual disability, and genetic disorders, positive prenatal screening, ultrasound abnormalities, teratogen exposure, and consanguinity. Apart from clinical reproductive genetics, Jennifer’s interests include ethical considerations in genetics and genetic counseling as well as the education of the next generation of genetic counselors. Jennifer holds a Master of Science degree in genetic counseling from the University of California, Irvine and a Bachelor of Science degree in genetics from the University of California, Davis. Jennifer is a member of the National Society of Genetic Counselors (NSGC) and the society’s prenatal special interest group.
M.S.Joanna is a licensed, board-certified genetic counselor who has specialized in carrier screening and reproductive genetics for more than five years. Prior to joining Invitae, Joanna was a research genetic counselor specializing in the genetic causes of autism spectrum disorder at Boston Children’s Hospital. She obtained a Bachelor of Science in Biological Sciences from the University at Buffalo and a Master of Science in Genetic Counseling from Arcadia University. Joanna is a member of the National Society of Genetic Counselors and the society’s ART special interest group.
M.S., LCGCRachel is a board-certified genetic counselor. Prior to joining Invitae she worked in clinical care for over 7 years providing genetic counseling directly to patients and families at-risk for hereditary disease. She previously worked for HealthEast Care system in Minnesota specializing in oncology, hematology and cardiology genetics. Before that, she worked as a genetic counselor for the Virginia Piper Cancer Institute of Allina Health in Minnesota. In addition to providing patient care in these roles, she developed many system-wide protocols for genetics services, trained other genetic counselors, and provided education to a wide array of healthcare professionals and patient groups. Rachel is a member of the National Society of Genetic Counselors (NSGC) as well as the Cancer, Cardiovascular, and Precision Medicine Special Interest Groups. Rachel holds a Master of Science in Genetic Counseling from the University of Minnesota and Bachelor of Science in Biomedical Science from St. Cloud State University. Rachel has done research on how the practice of genetic counseling is perceived among underserved populations and has a passion for creating broader access to genetic information and precision medicine in routine care.
M.S.Darlene is a board-certified genetic counselor with nearly 10 years of clinical and laboratory genetic counseling experience. Before joining Invitae, Darlene was the lead genetic counselor of clinical microarray services at GeneDx. While in that role, Darlene specialized in copy number analysis and interpretation. She was also an integral part of the GeneDx prenatal genetics program and supervised the genetic counseling assistants. Darlene is an active member of the National Society of Genetic Counselors (NSGC). She holds a Master of Science in genetic counseling from the University of Arkansas for Medical Sciences and a Bachelor of Science from Baylor University, where she majored in biology.
M.S., CGCStacie is a board certified genetic counselor with 27 years of experience. She spent 22 years in clinical practice working in prenatal and pediatric genetics, with an emphasis on inborn errors of metabolism and newborn screening. She spent the last 15 years of clinical practice working at Nemours Children’s Clinic, Winnie Palmer Hospital for Women and Children, Florida Hospital for Children and AdventHealth High Risk Pregnancy Consultants all in Orlando, FL. She transitioned into an industry genetic counselor role 4.5 years ago, working as a medical science liaison with Counsyl. Her primary focus was on provider education for expanded carrier screening and non-invasive prenatal screening. At Counsyl, she was the co-creator and facilitator for the industry genetic counselor clinical rotation for genetic counseling students. She is a member of the National Society of Genetic Counselors and the Florida Association of Genetic Counselors. She obtained her undergraduate degree in psychology from The University of Colorado, Boulder, and went on to pursue a Master of Science degree in genetic counseling from Sarah Lawrence College.
M.S., LCGCNatalie is a licensed, board-certified genetic counselor with over 5 years of experience providing genetic counseling to patients in a variety of clinical areas. Prior to coming to Invitae, Natalie was a counselor at Kaiser Permanente, San Francisco in reproductive, cancer, and general genetics. Prior to that, Natalie worked at the Center for Reproductive Health at the University of California, San Francisco, providing genetic counseling for couples and individuals hoping to start or continue a family. Natalie is passionate about making complex genetic concepts accessible and understandable to all so that people can have more advocacy in their own medical care. Natalie holds a Master of Science in Genetic Counseling from Brandeis University and a Bachelor of Science in Molecular, Cellular, Developmental Biology from the University of California, Santa Cruz.
M.S.Melissa is a licensed, board-certified genetic counselor with more than 15 years of experience in reproductive and prenatal genetics. She has provided clinical care in both academic and industry-based settings, including Baylor College of Medicine, University of Texas Health Science Center at Houston and Obstetrix/MEDNAX. Melissa’s passion is ensuring all patients, regardless of background or location, have access to high-quality genetic testing and counseling services. Melissa is an active member of the National Society of Genetic Counselors (NSGC), including the Prenatal and ART/Infertility special interest groups. She also serves as an advisory board member for the Baylor College of Medicine Genetic Counseling Program. She obtained her undergraduate degree with a major in Behavioral Neuroscience from Lehigh University and went on to pursue a Master of Science in Genetic Counseling from the University of Pittsburgh.
M.S., LCGCMichelle is a licensed, board-certified genetic counselor with over 20 years of experience in reproductive health and clinical genetics. Michelle has worked in a variety of settings spanning both academic medicine and commercial genetics laboratories, including the University of Texas-Houston Medical School, the University of California, San Francisco, LabCorp, and CombiMatrix. Michelle is passionate about empowering patients and healthcare providers to better understand complex genetic and medical information as a way of personalizing medical care and bringing genetics into mainstream medicine. Michelle is an active member of the National Society of Genetic Counselors, the American College of Medical Genetics, and the American Society of Reproductive Medicine, and serves on the editorial board of Lab Tests Online. Michelle holds a Master of Science degree in genetic counseling from the University of Texas Graduate School of Biomedical Sciences and a Bachelor of Science in cellular and molecular biology from the University of Washington.
MGC, LCGCVaish is a board-certified genetic counselor with over 7 years of experience. Prior to joining Invitae, she was a laboratory genetic counselor at Recombine/Cooper Genomics. Before that she worked as a prenatal genetic counselor at Cedars-Sinai Medical Center and as a pediatric genetic counselor at the Children’s Hospital of Los Angeles. Vaish is an active member of the National Society of Genetic Counselors (NSGC) and NSGC's Prenatal and ART/Infertility special interest group. She holds a Master’s in Genetic Counseling from the University of Maryland, Baltimore and a Bachelor of science degree in genetics and cellular development from the University of Minnesota.
MGCJackie is a licensed, board-certified genetic counselor with nearly 10 years of experience as a laboratory genetic counselor. Prior to joining Invitae in 2015, Jackie was a laboratory genetic counselor at GeneDx specializing in cardiovascular genetic testing and diagnostic exome sequencing. Jackie is an active member of the National Society of Genetic Counselors (NSGC). She holds a Master of Science in Human Genetics with a specialization in genetic counseling from Howard University and a Bachelor of Science in Biology from the University of Virginia.
MGCChris is a licensed, board-certified genetic counselor. He joined Invitae in 2014 and has over ten years of combined clinical counseling and laboratory experience. Chris has worked at the University of Chicago Genetic Services Laboratory and the Centre for Clinical Genomics in Vancouver, British Columbia. Chris has also previously provided genetic counseling in prenatal, general pediatric, newborn screening and specialty (neurogenetics and ophthalmology) clinics. Chris is a Clinical Instructor in the Department of Medical Genetics at the University of British Columbia, and he is an active member of the National Society of Genetic Counselors (NSGC) and the Canadian Association of Genetic Counsellors. He holds a Master of Science in Human Genetics from Sarah Lawrence College and a Bachelor of Science in Biochemistry from the University of Waterloo.
M.S.Yi-Lee is a licensed, board certified genetic counselor. Before joining Invitae, she worked in clinic seeing pediatric and adult patients for cardiovascular indications, and established genetic services in an ophthalmological clinic focusing on retinal diseases at the Medical College of Wisconsin. Yi-Lee’s interests lie in genetics education and she has designed and delivered lectures on inherited cardiovascular disease to medical students, graduate students, and fellows. She began her career providing risk assessment and genetic counseling for prenatal indications at the University of Illinois at Chicago. Yi-Lee holds a Master of Science in Genetic Counseling from Northwestern University and a Bachelor of Science Honours in Biochemistry, Specialization in Biotechnology and Genetic Engineering from McMaster University. At Invitae, she is part of the Clinical Consultation Services team. She is a member of the National Society of Genetic Counselors (NSGC) and the Cardiovascular and Industry Special Interest Groups.
MGC, LCGCSheila Upton is a licensed, board-certified genetic counselor with more than 17 years of clinical experience. Prior to joining Invitae, Sheila was the Senior Genetic Counselor in the Medical Genetics Program at Dartmouth Hitchcock Medical Center, providing genetic counseling for a wide range of pediatric and adult genetic disorders. She also specialized in cardiogenetic and neurogenetic disorders and was part of the DHMC Huntington Disease Center for Excellence clinic. She obtained her Bachelor of Arts degree from Cornell University and her Masters in Genetic Counseling from the University of Maryland, Baltimore. Sheila is a member of the National Society of Genetic Counselors (NSGC) and the American College of Medical Genetics and Genomics (ACMG).
M.S., LCGCJulia is a licensed, board-certified genetic counselor with more than 12 years of experience. Specializing in reproductive health and women’s genetics, she has provided clinical care in both academic and industry-based settings, including Genzyme Genetics, Emory Genetics, and UMass Medical Center and Medical School. Her primary interests are expanded carrier screening and increasing access to quality genetic care through alternative service delivery models. She obtained her undergraduate degree from McDaniel College and went on to pursue a Master of Science in Genetic Counseling from Brandeis University. Julia is a member of the National Society of Genetic Counselors (NSGC) and the society’s ART special interest group.
M.S.Stacey is a licensed and board-certified genetic counselor with over two decades of experience in clinical, research, and laboratory settings. Prior to joining Invitae, she was a clinical product manager and genetic counselor at Courtagen Life Sciences, a diagnostic laboratory specializing in pediatric neurological conditions and mitochondrial disease. Her other professional experience includes prenatal counseling at Genzyme Genetics, coordinator of the Lysosomal Storage Disease Research Center at Cedars-Sinai Medical Center and Senior Genetic Counselor participating in pediatric, metabolic, and specialty clinics at Children’s Hospital Los Angeles. She has particular interest in mitochondrial disease and is involved with the MseqDR Expert Panel group. She holds a Master of Science in Genetic Counseling from California State University Northridge, a Master of Traditional Oriental Medicine from Emperor’s College, and a Bachelor of Science in Cell and Molecular Biology from the University of California Los Angeles.
Michael J. Ackerman
M.D., Ph.D.Dr. Ackerman is the Windland Smith Rice Cardiovascular Genomics Research Professor and Professor of Medicine, Pediatrics, and Pharmacology at the Mayo Clinic in Rochester, Minnesota. He is a consultant in cardiovascular diseases and pediatric cardiology and serves as director of Mayo Clinic’s Long QT Syndrome Clinic and the Windland Smith Rice Sudden Death Genomics Laboratory. He is co-director of Mayo’s translational genomics program in hypertrophic cardiomyopathy. Dr. Ackerman was born and raised in Iowa. He graduated valedictorian from Sheldon High School in 1984 and graduated summa cum laude from Luther College in Decorah, Iowa, in 1988 with majors in chemistry and mathematics. He received his M.D. and Ph.D. degrees from Mayo Medical School and Mayo Graduate School in 1995 and completed residency (pediatrics) and fellowship (pediatric cardiology) training in the Mayo Graduate School of Medicine in 2000. He has been a faculty member of Mayo Clinic since July 2000. As director of Mayo Clinic’s Long QT Syndrome/Inherited Arrhythmia Syndrome Clinic and Windland Smith Rice Sudden Death Genomics Laboratory, Dr. Ackerman strives to fulfill the two-fold objective of medical education and biomedical research as stated by Dr. Charles H. Mayo: “to heal the sick and to advance the science.”
M.D.Dr. Michael Alper co-founded Boston IVF in 1986. He is double board-certified in Obstetrics and Gynecology as well as Reproductive Endocrinology and Infertility. He specializes in all aspects of infertility care. Dr. Alper is also an Associate Clinical Professor in the Department of Obstetrics, Gynecology, and Reproductive Biology at Harvard Medical School, where he teaches the next generation of fertility experts and performs crucial research to improve future care. He contributes to infertility articles, abstracts, and letters, and actively lectures at scientific meetings throughout the world. He is the author of The Boston IVF Handbook of Infertility, which is widely considered the preeminent print resource in the field of reproductive medicine. His continued dedication to improving the efficiency of fertility treatments has led to Boston IVF becoming the first ISO-certified IVF clinic in North America. This prestigious designation underscores his commitment to quality and safety in the field. Dr. Alper grew up in Canada and received his undergraduate and medical school degrees from McGill University in Montreal. Following medical school, he spent an internship year at the University of Toronto before being accepted to the Harvard Medical School Obstetrics and Gynecology Residency Program at the Beth Israel Hospital in Boston. After completing his OB/GYN residency, Dr. Alper returned to Canada to focus on clinical research in reproductive medicine at the University of Ottawa. Subsequently, he returned to Boston to complete his research fellowship in reproductive endocrinology in the Department of Obstetrics and Gynecology at Beth Israel Hospital and the Harvard Medical School in Boston. IVF technology was in its very early stages in 1986 when Dr. Alper co-founded Boston IVF, one of the nation’s first free-standing IVF centers. The goal was to transform state-of-the-art technologies into a patient-centered, outpatient setting. Dr. Alper has lead Boston IVF as its Medical Director for over 20 years and remains instrumental in helping to make it one of the most well-respected, academically-affiliated IVF centers in the world.
Olaf Bodamer M.D.,
Ph.D., FACMG, FAAPDr. Bodamer is a board certified pediatrician, clinical and biochemical geneticist who is at the nexus of patient centered, translational science where “bench meets the bedside.” As associate chief of the Division of Genetics and Genomics he provides leadership to its clinical operation and the clinical diagnostic laboratory. Dr. Bodamer is also an associate professor at Harvard Medical School. Following his postdoctoral training at Baylor College of Medicine, Dr. Bodamer has been tenured faculty at the University Medical School Vienna and more recently at the University of Miami where he was professor of human genetics, molecular biology and biochemistry. His research focuses on the dynamic integration and application of multiple “OMICS” (genome, transcriptome, methylome, metabolome, microbiome) to different disease and health states including selected orphan diseases, premature birth, and pregnancy. Using a systems biology approach his research aims to identify factors that critically impact phenotypic severity and variability while being amenable to therapeutic interventions. Dr. Bodamer is member of several editorial boards and has published more than 140 peer-reviewed articles and book chapters.
Sc.M., CGC Julie is a senior genetic counselor at the Kennedy Krieger Institute in Baltimore, Maryland, where she counsels and participates in the diagnostic evaluation and management of pediatric and adult patients with a wide range of neurogenetic disorders and developmental disabilities. She is also involved in clinical research in the Hugo W. Moser Research Institute at KKI. Her areas of expertise include leukodystrophies, myopathies, movement disorders, epilepsy, intellectual disability, and autism. Julie and her colleagues were early adopters of whole-exome sequencing, and she has extensive experience with clinical implementation of this technology. Julie is a key opinion leader in her field and frequent speaker at national meetings. Julie received her Master’s degree from the Johns Hopkins/National Human Genome Research Institute Genetic Counseling Training Program, for which she now serves on the Executive Committee and is actively involved in mentoring and clinical supervision of students. Julie is a member of the National Society of Genetic Counselors and is certified by the American Board of Genetic Counseling.
M.D., M.A. Dr. Demmer is currently the Director of Genetics and the Associate Pediatric Residency Program Director at Levine Children’s Hospital in Charlotte, NC. She also serves as a member of the Board of Directors of the ACMG and has been a past Chair of the Program Committee as well as a member of the MOC Committee and Membership Committee. She is a current member of the ABMS Committee on Continuing Certification. Previously, Dr. Demmer served as President of the ABMGG, as well as President of the APHMG. She was President of the Medical Genetics Residency Program Directors Group and is the current Chair of the ACGME Review Committee for Medical Genetics and Genomics. Dr. Demmer divides her time between Clinical Genetics, Medical Education and Clinical Research. She is an author on over 75 peer-reviewed works including publications, reviews, and book chapters. Her research interests include dysmorphology, applications of genetic and genomic testing in clinical practice, ethics, and medical education. Dr. Demmer graduated from Dartmouth College and then received her M.D. and M.A. (Biochemistry) from Washington University in St. Louis. Subsequently she completed her Pediatrics Residency at St. Louis Children’s Hospital and Medical Genetics Fellowship at Washington University. Dr. Demmer joined the University of Massachusetts Medical School where she was the Division Chief in Genetics from 1995 to 2002. She then moved to Tufts University School of Medicine where she served as Professor of Pediatrics, Division Chief of Genetics and Metabolism, Program Director for the Genetics Residency,and Director for the Medical Student Genetics Course until 2012.
M.D., Ph.D.Dr. Green is a physician-scientist and entrepreneur with more than 10 years of experience building and operating innovative scientific organizations. He is currently an Entrepreneur in Residence at Third Rock Ventures, where he leads the formation of startup biotechnology companies. Eric previously was the head of translational research at MyoKardia, a biotechnology company discovering and developing drugs for patients with genetic heart diseases. Prior to joining Third Rock, Eric co-founded ILab Solutions, a provider of web-based software and services designed to streamline scientific research, which was acquired by Agilent and Respira Design, a medical device company treating asthma in the developing world, which won the Stanford $50K Entrepreneurship Challenge. He is a board-certified physician with training in internal and cardiovascular medicine from Brigham and Women’s Hospital. He received an M.D. and Ph.D. in Chemical and Systems Biology from Stanford University and an A.B. in History and Science from Harvard College.
M.D., Ph.D. Dr. McNally is a cardiologist and geneticist who works with patients and their families, helping them understand genetic risks for inherited cardiovascular disorders. She joined Northwestern University in September 2014 to lead its Center for Genetic Medicine, which is committed to exploring and defining genetic variability and to using all available information on the human genome to better inform healthcare decisions. Her group has devised new methods for surveying human genetic data and has established animal and cell-based models of genetic diseases. Dr. McNally is supported by the National Institutes of Health, the Department of Defense and private foundations. She was president of the American Society for Clinical Investigation from 2011 to 2012 and serves as an advocate through her work with the Muscular Dystrophy Association, Parent Project Muscular Dystrophy and the American Heart Association. Dr. McNally received an Established Investigator Award by the AHA and a Distinguished Clinical Scientist Award by the Doris Duke Charitable Foundation.
M.D. Dr. Mary Norton is a perinatologist and geneticist, and is Professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of California, San Francisco. She is Director of the Prenatal Diagnostic Center at UCSF and co-Director of the UCSF Center for Maternal-Fetal Precision Medicine. She is also the President of the Perinatal Quality Foundation, past President of the Society for Maternal-Fetal Medicine, and Chair of the Publications Committee of the SMFM. Her clinical and research interests include genetic testing and its application to prenatal screening and diagnosis. She focuses on the unique aspects of translating new technologies into improved care for pregnant women and their fetuses. She is a co-Principal Investigator on a current multicenter collaborative study of whole-exome sequencing for the assessment of fetal structural abnormalities. Much of her recent research has involved cell free DNA screening and implementation into prenatal care.
M.D., Ph.D., FACMG Dr. Saitta is a pediatric geneticist and Clinical Director of the Center for Personalized Medicine at Children’s Hospital Los Angeles and Associate Professor of Clinical Pathology at Keck USC School of Medicine. She completed her undergraduate studies with honors at Johns Hopkins University receiving the Martin G. Larrabee Award for outstanding research in biophysics, followed by M.D./Ph.D. training in the Gibbon Scholars Program at Thomas Jefferson University in Philadelphia. She trained in pediatrics at St. Christopher’s Hospital for Children and in clinical genetics at Children’s Hospital of Philadelphia, where her research involved work on disorders of chromosome 22q, its structure, and sequence for the Human Genome Project. She remained as faculty at CHOP/University of Pennsylvania from 2001 to 2011 with NHLBI supported research on the mechanisms of genomic disorders and congenital cardiac defects. She was recruited by the late Dr. David Rimoin as Associate Director of Clinical Genetics at Cedars-Sinai and Associate Professor of Pediatrics at UCLA. In 2015, she joined Children’s Hospital Los Angeles, where she provides clinical support and interpretation for whole exome, chromosome microarray, and focused exome testing for constitutional disorders and pediatric cancer testing using the newly developed OncoKIDS RNA-DNA platform. Her research interests include genomic disorders, particularly of chromosome 22q11, which is an area of her expertise and focus of publications. She directs the multidisciplinary 22q11 disorders clinic at UCLA and participates in program project studies involving these disorders at UCLA and as part of the 22q International Consortium.
M.D., Ph.D. Dr. Sankar is Professor of Neurology and Pediatrics and Chief of Pediatric Neurology at the David Geffen School of Medicine at the University of California, Los Angeles. He holds the Rubin Brown Distinguished Chair in Pediatric Neurology. He is a member of an active pediatric epilepsy program at UCLA that is well known internationally for many advances in pediatric epilepsy surgery. Dr. Sankar has authored more than 250 research articles, reviews, and book chapters. He has also co-edited textbooks on pediatric epilepsy as well as the applications of basic science in epilepsy research. He is a member of the editorial board of Epilepsy & Behavior and has served on the editorial boards of Epilepsia and Epilepsy Currents. He is an elected Fellow of the American Academy of Neurology and an elected member of the American Pediatric society. Dr. Sankar is a member of the Professional Advisory Board of the Epilepsy Foundation. He has been a member of the Commission on Neurobiology of the International League Against Epilepsy and presently serves on the Commission’s Task Force for the Workshop on the Neurobiology of Epilepsy (WONOEP). Dr. Sankar is a graduate of the University of Bombay, India. He obtained his Ph.D. from the University of Washington in Medicinal Chemistry and was involved in teaching and research for several years prior to entering Tulane Medical School, where he obtained his M.D. He trained in pediatrics at the Children’s Hospital of Los Angeles. He completed his training in neurology and pediatric neurology at UCLA.
M.D. Dr. Sullivan is Associate Professor of Neurology and Pediatrics at the University of California San Francisco and Director of the UCSF Pediatric Epilepsy Center at Benioff Children’s Hospital. As a pediatric epilelptologist, he cares for all children with various forms of epilepsy but has specific clinical and research interests in Dravet Syndrome, PCDH19-related epilepsy and the evaluation of children for epilepsy surgery. Dr. Sullivan is a member of the American Epilepsy Society and serves on a number of boards including the Medical Advisory Board for the Dravet Syndrome Foundation, Chair of the PCDH19 Alliance Scientific Advisory Board, Chair of the Pediatric Epilepsy Research Consortium (PERC) Steering Committee, and a past Chair of the Epilepsy Foundation of Northern California Board of Directors, He is a graduate of Union College and Albany Medical College. He completed a pediatric residency at the Children’s Memorial Hospital of Northwestern University in Chicago, where he spent an additional year as pediatric chief resident. He then completed his Neurology, Child Neurology, and Epilepsy training at the Hospital of University of Pennsylvania and The Children’s Hospital of Philadelphia before taking his first faculty position at UCSF in 2007. He lives in Marin with his wife Sara, a pediatrician turned Urban Zen Integrative Therapist, and their two daughters Grace and Ella.
Oncology Advisory Board
Eliezer Van Allen
M.D. Dr. Van Allen is an Assistant Professor of Medicine at Harvard Medical School, a clinician at Dana-Farber/Partners Cancer Care, and an Associate Member at the Broad Institute of MIT and Harvard. His research focuses on computational cancer genomics, the application of new technologies such as massively parallel sequencing to precision cancer medicine, and resistance to targeted therapeutics. As both a computational biologist and medical oncologist, he has specific expertise in clinical computational oncology and the development of algorithms to analyze and interpret genomic data for clinically focused questions. Overall, his research will make important contributions to the field of precision cancer medicine and resistance to targeted therapeutics via expertise and study in translational and clinical bioinformatics. Originally from Los Angeles, CA, he studied Symbolic Systems at Stanford University, obtained his M.D. from UCLA, and completed a residency in internal medicine at UCSF before coming to Boston and completing a medical oncology fellowship at the Dana-Farber/Partners Cancer Care program.
Lucy A. Godley
M.D., Ph.D. Dr. Godley began her scientific career in several laboratories: Sally/Vincent Marchesi (Yale), Don Wiley (Harvard), and Harold Varmus (UCSF/NIH). She completed her medical training at Northwestern University followed by an internal medicine/hematology-oncology residency/fellowship at The University of Chicago, where she joined the faculty in 2003. Her laboratory studies inherited hematopoietic malignancies and the control of differentiation potential in cancer cells by modified cytosines. As a physician-scientist with research and clinical responsibilities, Dr. Godley seeks to understand disease on a molecular basis and is able to bring that perspective to the care of her patients.
Emmanuel S. Antonarakis M.D. Dr. Antonarakis is an associate professor of oncology and urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, and the Director of Prostate Cancer Medical Oncology Research. He graduated from the University of Wales College of Medicine (United Kingdom) in 2003, and then completed a residency in internal medicine at the Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at the Johns Hopkins Hospital. Since 2010, he has been on the Johns Hopkins faculty as an attending physician and translational researcher in the Department of Oncology. Dr. Antonarakis’ clinical interest is the management of prostate cancer and other genitourinary malignancies.
His research focuses on drug development and clinical trial design for patients with prostate cancer, as well as cancer genomics. More specifically, he is interested in developing novel androgen-directed therapies as well as immunotherapies for men with recurrent or advanced prostate cancer, and using cancer genomics to inform precision oncology approaches. He also has an interest in liquid biomarker development, specifically the clinical validation of the AR-V7 marker as well as DNA repair markers and their therapeutic implications. He is currently the PI of several phase II and III prostate cancer trials, and is an active member of the Prostate Cancer Clinical Trials Consortium (PCCTC) and the Eastern Cooperative Oncology Group (ECOG) as well as the NCI Prostate Cancer Task Force and the NCCN Prostate Cancer Panel. He serves on the editorial board of several oncology journals, including the Journal of Clinical Oncology. He is the author of more than 220 peer-reviewed articles, several book chapters, and has edited a textbook about AR signaling in cancer.
M.D. Dr. Borazanci is a Medical Oncologist and Clinical Investigator at the HonorHealth Research Institute (HHRI) located on the HonorHealth Shea Campus in Scottsdale, Arizona. He holds adjunct appointments at the Translational Genomics Research Institute (TGen) and the University of Arizona as a clinical assistant professor. Dr. Borazanci obtained a Master of Science in biochemistry and molecular biology and completed medical school at Louisiana State University Health Center in Shreveport. His specialty is gastrointestinal oncology, with a focus on pancreatic cancer. Dr. Borazanci is a principal investigator for several clinical trials, many of which are in phase I and first-in-human studies. His focus is working with his colleagues at TGen along with several collaborators to bring forth new and promising agents as treatment options for patients with cancer. He is also the director of the early detection program at HHRI, with a focus on discovering newer methods for the early detection of several cancers, including pancreatic.
M.S., LGCHeather has been the associate director for biospecimen research for The Ohio State University Comprehensive Cancer Center (OSUCCC) since January 2015. She is a professor in the Department of Internal Medicine and associate director of the Division of Human Genetics. She is also a professor in the Department of Internal Medicine and associate director of the Division of Human Genetics. She is the PI of both the Total Cancer Care® (TCC) protocol and the Ohio Colon Cancer Prevention Initiative (OCCPI). Heather is an internationally recognized cancer genetic counselor with a particular emphasis on universal tumor screening for Lynch syndrome. Heather was on the Board of Directors of the National Society of Genetic Counselors from 2003 to 2004 and of the American Board of Genetic Counseling from 2006 to 2011, serving as president in 2009 and 2010. She is currently an elected council member of the Collaborative Group of the Americas on Inherited Colorectal Cancer. Heather completed her bachelor of science degree in molecular genetics at The Ohio State University in 1993. She attained her master’s degree in human genetics from Sarah Lawrence College in 1995. She received certification from the American Board of Genetic Counseling in 1996. She worked as a cancer genetic counselor at Memorial Sloan-Kettering Cancer Center in Manhattan before moving to The Ohio State University in 1997.
Pasi A. Jänne
M.D., Ph.D. Dr. Jänne is the director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School. He is also the director of the Belfer Center for Applied Cancer Science at the Dana Farber Cancer Institute. Dr Jänne’s research combines laboratory-based studies, with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests center around understanding and translating the therapeutic importance of oncogenic alterations in lung cancer. He has made seminal therapeutic discoveries, including being one of the co-discoverers of EGFR mutations, and findings from his studies have helped define the current treatment paradigm for EGFR mutant lung cancer patients. He led the first-in-man clinical trial of the mutant selective EGFR inhibitor osimertinib which was approved by the Food and Drug Administration in 2015.
M.S., LGC Jilliane is the current co-chair of the Somatic Subcommittee for the National Society of Genetic Counselors. She currently works as an IMPACT program cancer navigator. She previously worked as a clinical genetic counselor at the Dana-Farber Cancer Institute and UMass Memorial Medical Center specializing in the use of somatic testing in the clinical cancer genetics setting.
Gary H. Lyman
M.D., MPH, FASCODr. Lyman is a member of the Public Health Sciences and Clinical Research Divisions at the Fred Hutchinson Cancer Research Center where he serves as senior lead, healthcare quality and policy in the Hutchinson Institute for Cancer Outcomes Research. He is also professor of medicine at the University of Washington School of Medicine as well as adjunct professor in the Schools of Public Health and Pharmacy at the University of Washington. Dr. Lyman received his undergraduate and medical degrees from the State University of New York at Buffalo and completed his internal medicine residency at the University of North Carolina at Chapel Hill and his hematology/oncology fellowship at the Roswell Park Memorial Institute. Dr. Lyman subsequently pursued a postdoctoral fellowship in biostatistics at the Harvard School of Public Health and the Dana Farber Cancer Center. After joining the faculty of the University of South Florida College of Medicine, Dr. Lyman served as assistant, associate and then full professor of medicine and director of medical oncology. Shortly after his arrival, Dr. Lyman began working with Lee Moffitt and the leadership of the University to develop plans for the eventual H. Lee Moffitt Cancer Center and Research Institute where he served as the founding chief of medicine and director of the Division of Medical Oncology as well as associate chairman of the Department of Medicine at USF. During this period, he also served as professor of medicine and professor of epidemiology and biostatistics at the University of South Florida. Upon leaving Moffitt in 2000, Dr. Lyman held positions as the Thomas Ordway Endowed professor of medicine and cancer center director at the Albany Medical College, and subsequently professor of medicine, associate cancer center director and director of health services and outcomes research at the University of Rochester and Strong Memorial Hospital. Prior to relocating to his present position, Dr. Lyman served as professor of medicine and director of comparative effectiveness and outcomes research- oncology at Duke University and the Duke Cancer Institute and a senior fellow at the Duke Center for Clinical Health Policy Research. Dr. Lyman is active with the American Society of Clinical Oncology, serving recently on the ASCO Board of Directors, chairing the Guideline Methodology Committee as well as several individual guidelines including those related to the prevention and treatment of venous thromboembolism in cancer, sentinel node biopsy in early-stage breast cancer and melanoma, and appropriate chemotherapy dosing in obese patients with cancer. Dr. Lyman chairs the ASCO Task Force on the role of observational research in clinical practice and the ASCO working group on biosimilars in oncology. He is also a member of the Value of Cancer Care Task Force and Cancer Research Committee along with several additional roles within the Society. In 2010, Dr. Lyman received the ASCO Statesman Award. He is also active in the American Association for Cancer Research and the Institute of Medicine as well as the American Society of Hematology where he serves on the Quality and Guideline Oversight Committees and chairs the forthcoming guideline on cancer- associated thrombosis. Finally, Dr. Lyman is active with SWOG serving as executive officer for the SWOG NCORP and the Immunotherapy, Symptom Management and Quality of Life, Cancer Care Delivery Research, and Palliative Care Committees and is on the board of directors of the Hope Foundation. Dr. Lyman is editor-in-chief of Cancer Investigation and on the editorial board of the Journal of Clinical Oncology, the Journal of Global Oncology, and several other specialty journals. In addition to serving as a fellow of ASCO, Dr. Lyman is a fellow of the Royal College of Physicians (Edinburgh), the American College of Physicians, and the American College of Preventive Medicine. Dr. Lyman’s research interests include precision medicine based on personalized cancer treatment and supportive care, comparative effectiveness and outcomes research related to biomarkers and targeted therapies, mathematical and statistical prognostic and predictive models, advanced methods of evidence synthesis in support of clinical practice guidelines, and population studies of patterns of cancer treatment and the impact of health disparities on the quality of cancer care. Dr. Lyman has authored or edited more than 15 books and more than 600 articles in the scientific literature.
Genetic Counseling Advisory Board
M.S.Sharon earned her master’s in genetic counseling from California State University, Northridge and her master’s in public health from the University of California, Los Angeles.She has over 12 years of clinical genetic counseling experience working with patients and families in fertility, prenatal, pediatric, and oncology specialties. Passionate about making genetic testing equitable and accessible to as many individuals as possible, Sharon is interested in exploring how technology such as telemedicine can break down healthcare barriers. Sharon is currently the Genetics Program Manager for Sutter Health Bay and oversees genetic counseling operations in multiple locations across the Greater Bay Area in California. She is also an adjunct faculty in Samuel Merritt University’s School of Nursing and in Keck Graduate Institute’s Master of Science in Human Genetics and Genetic Counseling program. When not at work, you can usually find Sharon tending to her vegetable garden, biking with her family, or enjoying a true crime novel.
M.S.Andrea is a genetic counselor specializing in hereditary cancer risk. She received her master’s degree in genetic counseling from the Mount Sinai School of Medicine in New York City in 2004 and has worked at both Mount Sinai and the Fox Chase Cancer Center in Philadelphia. Over the course of her career, she has provided genetic counseling services for many different cancer types, worked on a variety of research studies, published numerous abstracts, academic posters and journal articles, taught, supervised and mentored genetic counseling trainees, and provided educational lectures to medical professionals and community members. She has volunteered in a number of roles including co-chair of the Cancer Special Interest Group for the National Society of Genetic Counselors, member of the Cancer Genetics/Genomics Committee for the Cancer Advisory Board of the State of Pennsylvania, and member of the 2019 American College of Obstetricians and Gynecologists Early Onset Breast Cancer Evidence Review Conference. You can follow Andrea on Twitter@AForman_CGC.
M.S. Brandie is a licensed genetic counselor in the Genomic Medicine Institute and Sanford R. Weiss Center for Hereditary Colorectal Neoplasia at the Cleveland Clinic. She has been practicing there since 2006 upon graduating from the University of Cincinnati graduate program in genetic counseling. Ms. Leach counsels patients with or at risk for hereditary cancer syndromes, with a particular interest in hereditary colorectal cancer conditions. In 2007 she established genetic counseling services within the Digestive Disease Institute at the Cleveland Clinic. She coordinates the Cleveland Clinic Universal Lynch Syndrome Screening Program and conducts research on the hamartomatous polyposis syndromes. She has served in various leadership positions within the National Society of Genetic Counselors, was on the board of Hereditary Colon Cancer Takes Guts, and is the past president of the Collaborative Group of the Americas on Inherited Colorectal Cancer Council. She is currently on the board of directors for the Lynch Syndrome Screening Network.
M.S. John is the program manager for the Genetic Counseling Clinic at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center. He is also actively involved as a genetic counselor in clinical cancer genetics and sees patients for hereditary cancer risk assessment. He is actively involved in research at Cedars-Sinai related to genetic testing outcomes. Other interests involve the supervision of graduate genetic counseling students as well as undergraduates and volunteers interested in pursuing genetic counseling as a career. Prior to joining Cedars-Sinai Medical Center, John worked as a cancer genetic counselor at St. Joseph Hospital and affiliated oncology clinics at Mission Hospital and St. Jude Hospital. John completed his Bachelor of Arts degree in genetics at Rutgers University. He received his Master of Science degree in genetic counseling from the University of California, Irvine. John is certified by the American Board of Genetic Counseling, licensed by the California Department of Public Health, and is a member of the National Society of Genetic Counselors.
M.S., CGC Stacy received her undergraduate degree in chemistry from the University of North Carolina at Chapel Hill and completed her graduate coursework in genetic counseling at the University of South Carolina. She has been an employee of Atrium Health (formerly Carolinas HealthCare System) since 2006. Prior to joining the Cancer Genetics Program, Stacy worked in the Molecular Pathology Laboratory with the Carolinas Laboratory Network where she performed genetic testing in multiple areas, including oncology. During her eight years as a genetic counselor at Levine Cancer Institute (LCI), Stacy has proven herself to be an integral team member in helping to establish both the virtual cancer genetics program and the pediatric cancer genetics clinic, in addition to providing counseling to adult patients with personal and family histories of cancer.
M.S. Bitais a licensed board-certified genetic counselor specializing in cancer genetics. She received her master’s degree in human genetics and genetic counseling from Stanford University. Bita joined the City of Hope Division of Clinical Cancer Genomics in 2012, where she provides cancer genetics services for patients and families suspected to have a hereditary predisposition to cancer, with a focus on Li-Fraumeni syndrome. She is fluent in Spanish and Farsi, and is committed to advancing the provision of cancer genetics services to medically underserved and culturally diverse populations. Other clinical responsibilities include providing pro-bono cancer genetic counseling services to underserved Latino families through an outreach program established by the Division of Clinical Cancer Genomics and supported through government and foundations grants and compassionate funding. Current research projects include assessing the influence of pre-consultative interventions in the uptake of genetic counseling services in Latinas, and understanding the prevalence of somatic TP53 mutations and how they can confound genetic test results and clinical outcomes. She also serves on the Genetic Counseling Advisory Committee for the Li-Fraumeni Syndrome Association. She is an active member of the National Society of Genetic Counselors and the American Society of Human Genetics.
M.S. Sara is Assistant Director of the Cancer Genetics program at UT Southwestern Medical Center in Dallas/Ft. Worth, Texas. Sara received her Bachelor of Science in genetics from Texas A&M University and her master’s degree from the University of Minnesota in 2005. Currently, Sara leads 14 genetic counselors that provide hereditary cancer risk assessment in 16 clinical sites with over 4,800 patients served annually in the DFW area. Sara is a past co-chair of the Cancer Special Interest Group (SIG) of the National Society of Genetic Counselors (NSGC), and she has served in leadership positions on several committees on the state and national levels. She has lectured extensively and published articles regarding cancer genetics on the local and national level. Her research interests include genetic counseling workforce efficiency, service delivery models, and population screening.
M.S. Jaclyn is the lead genetic counselor of the Pediatric Cancer Genetic Risk Program and the Bone Marrow Failure and MDS Program at the Dana-Farber Cancer Institute and Boston Children’s Hospital. She graduated from the Johns Hopkins University joint training program with the National Human Genome Research Institute at the NIH in 2008. She joined Dana-Farber in 2012 after working in a busy general genetics clinic at Tufts Medical Center. At Dana-Farber, she co-led the establishment of the Pediatric Cancer Genetic Risk Program. Jaclyn is interested in the communication of genetic risk and health information to children and families, as well as identifying the genetic causes of cancer in children.
M.S. Jessica is a board-certified genetic counselor and the Associate Director of the Gastrointestinal Cancer Risk and Prevention Clinic at the University of Chicago Medicine. She received her bachelor’s degree in biological sciences from the University of Southern California and a master’s degree in genetic counseling from Northwestern University. Her clinical and research interests include hereditary gastrointestinal cancer susceptibility syndromes, hereditary pancreatitis, and incorporating clinical genetics into medical education curricula. Jessica is a core faculty member of the Northwestern University Graduate Program in Genetic Counseling, serving as a clinical rotation supervisor, a member of the Research Oversight Committee and the Internet Resource Task Force, an advisor and member of thesis committees, and a guest lecturer. She is also actively involved in educational programming, giving lectures and presentations to physicians and trainees within the University of Chicago Graduate Medical Education program and for the greater Chicagoland medical community.
M.S. Jennie graduated from the University of Utah with a Master of Science in genetic counseling. She is a licensed genetic counselor in Utah and Idaho. She joined the genetic counseling team at Huntsman Cancer Institute in 2017, where she provides cancer genetics services for patients and families suspected to have cancer predisposition syndromes. She has a special focus in Li-Fraumeni syndrome, hereditary hematological malignancies, and pediatric predisposition to cancer.
Estimate your out-of-pocket cost for Invitae tests related to a personal or family history of
breast, ovarian, colorectal, or uterine cancer.
Based on the insurance provided, the out-of-pocket cost estimate is
The amount shown above is an estimate of your out-of-pocket cost based upon the
information you entered about your health insurance coverage. It is not a confirmation
that the test has been authorized by your insurance provider. Your final cost may
vary based upon your health plan design, deductible, co-insurance, and out-of-pocket limits.
Learn More >
As part of Invitae’s dedication to making high-quality genetic testing affordable and
accessible, we also offer a patient pre-pay option of $250.
Learn More >
We could not determine an out-of-pocket estimate.
Please contact us for assistance.